On April 23, 2018 Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, reported that two scientific abstracts have been accepted for presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Free ASGCT Whitepaper), taking place May 16-19, 2018, in Chicago (Press release, Intellia Therapeutics, APR 23, 2018, View Source [SID1234525587]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The first presentation will share information relating to Intellia’s lead in vivo program, for transthyretin amyloidosis. The data being presented include results from an ongoing collaboration with researchers at the University of Porto in Portugal. The second presentation will focus on Intellia’s ongoing research collaboration with IRCCS Ospedale San Raffaele in Italy to develop CRISPR-edited, T-cell therapies to address hard-to-treat cancers. Intellia will also participate in an education session on RNA therapeutics.

Details of Intellia’s presentations are as follows:

"Rescue of Amyloid Deposition Phenotype after Single-Treatment CRISPR/Cas9 Gene Editing in a Humanized Mouse Model of TTR Amyloidosis"
Session: Neurologic Diseases (Including Ophthalmic and Auditory Diseases) I
Session date/time:Wed., May 16, 2018, 5:30-7:30 p.m. CT
Location: Stevens Salon C, D
"Hunting WT1-Specific T-Cell Receptors for TCR Gene Editing for Acute Myeloid Leukemia"
Session: Cancer – Immunotherapy, Cancer Vaccines I
Session date/time:Wed., May 16, 2018, 5:30-7:30 p.m. CT
Location: Stevens Salon C, D
"Lipid Nanoparticle-Based RNA Delivery: At the Intersection of Chemistry and Immunology"
Presenter: Jonathan Finn, Ph.D., executive director, Platform Biology
Session: Education Session 401 – RNA Therapeutics
Presentation date/time:Sat., May 19, 2018, 9-9:30 a.m. CT
Location: Salon A-1
In addition, the following Intellia collaborators will highlight aspects of their research efforts with the Company:

"Clinical Gene Editing Programs"
Presenter: Beverly Davidson, Ph.D., chief scientific strategy officer, Children’s Hospital of Philadelphia (CHOP); director, Raymond G. Perelman Center for Cellular and Molecular Therapeutics, CHOP; Arthur V. Meigs Chair in Pediatrics, CHOP; and professor, Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
Session: Pre-Meeting Program – Gene Editing Workshop
Presentation date/time:Tue., May 15, 11 a.m.-12 p.m. CT
Location: Continental B
"TCR Gene Transfer and TCR Gene Editing"
Presenter: Chiara Bonini, M.D., Ph.D., full professor, Università Vita-Salute San Raffaele; deputy director, Division of Immunology, Transplantation and Infectious Diseases; and head, Experimental Hematology Unit, Ospedale San Raffaele, Italy
Session: 100 Immune Responses to Cell and Gene Therapies, Mechanisms, Biomarkers and Therapeutic Interventions
Presentation date/time:Wed., May 16, 2018, 8-8:30 a.m. CT
Location: International Ballroom North
Abstracts will become available on the ASGCT (Free ASGCT Whitepaper) website on Mon., April 30th, at 11 a.m. CT.